Seeking Alpha EN

AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis

Mar 11, 2026 &03311111202631; 12:31 UTC seekingalpha.com

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -65/100

Moderate impact Medium-term (weeks)

WHAT THIS MEANS

UCB's Bimzelx demonstrated superior efficacy compared to AbbVie's Skyrizi in psoriatic arthritis treatment, potentially impacting market share in the immunology segment. This clinical setback could pressure AbbVie's revenue growth in this therapeutic area and strengthen UCB's competitive position.

AI CONFIDENCE

75% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

ABBV

ABBVStock

Expected to decline

Negative clinical trial outcome for Skyrizi in psoriatic arthritis reduces competitive advantage and future revenue potential in immunology segment

↑

UCB

UCBStock

Expected to rise

Bimzelx's superior efficacy strengthens market position and growth prospects in psoriatic arthritis treatment

⇅

IT→.MI

IT→.MIIndex

High volatility expected

Mixed impact on Italian healthcare sector; negative for AbbVie exposure, positive for UCB

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider reducing AbbVie positions and monitoring for further clinical data releases. UCB presents a tactical opportunity given Bimzelx's competitive advantage, though broader market conditions should be evaluated before initiating new positions.

KEY SIGNALS

Clinical trial setback for major revenue driverCompetitive market share loss in psoriatic arthritisBimzelx efficacy advantage validates UCB's R&D strategyPotential impact on AbbVie's guidance and pipeline valuation

SECTORS INVOLVED

HealthcarePharmaceuticalsImmunology

Analysis generated on Mar 12, 2026 at 01:26 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis

RELATED INTELLIGENCE